Medicamen Organics Ltd vs Sai Parenterals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Medicamen Organics Ltd is ₹ 25.6 as of 18 May 11:24 . The P/E Ratio of Medicamen Organics Ltd is 0 as of March 2024 .The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2024 . The Market Cap of Medicamen Organics Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2024 . The Dividend Payout of Medicamen Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sai Parenterals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Medicamen Organics Ltd

Medicamen Organics Limited was formerly incorporated on March 15, 1995 as Panchdeep Pharmaceuticals Limited', as Public Limited Company dated March 15, 1995 issued by the Registrar of Companies, Delhi and Haryana.
Subsequently, the name of Company changed to Medicamen Organics Limited' and a fresh Certificate of Incorporation on November 14, 1995 was issued by the Registrar of Companies, Delhi and Haryana at Delhi. Medicamen Organics are engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry Powders for Government (including both State and Central Governments) and Private Institutions as contract manufacturer / third party manufacturer.
The product portfolio consists of 84 products and comprises of wide range of drugs like, Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Proton Pump Inhibitor, Anti Histamine, Anti-Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral and Nonsteroidal anti-inflammatory drug (NSAIDS).

About Sai Parenterals Ltd

Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022. Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.

FAQs for the comparison of Medicamen Organics Ltd and Sai Parenterals Ltd

Which company has a larger market capitalization, Medicamen Organics Ltd or Sai Parenterals Ltd?

Market cap of Medicamen Organics Ltd is 30 Cr while Market cap of Sai Parenterals Ltd is 2,129 Cr

What are the key factors driving the stock performance of Medicamen Organics Ltd and Sai Parenterals Ltd?

The stock performance of Medicamen Organics Ltd and Sai Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Organics Ltd and Sai Parenterals Ltd?

As of May 18, 2026, the Medicamen Organics Ltd stock price is INR ₹26.0. On the other hand, Sai Parenterals Ltd stock price is INR ₹482.1.

How do dividend payouts of Medicamen Organics Ltd and Sai Parenterals Ltd compare?

To compare the dividend payouts of Medicamen Organics Ltd and Sai Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.